Pneumonia clinical trials at UC Irvine

• A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

  open to eligible people ages 18 years and up

  Evaluate the safety and effect of ORTD-1 on COVID-19 related pneumonia.

  Orange, California

• A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19)

  open to eligible people ages 18 years and up

  This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.

  Orange, California and other locations

• Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

  open to eligible people ages 18-100

  The study is a double-blind, randomized, placebo-controlled, adaptive design, multi-center, Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects.

  Orange, California and other locations

• Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

  open to eligible people ages 18 years and up

  This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

  Irvine, California and other locations

• The INSPIRE-ASP PNA Trial

  open to eligible people ages 18 years and up

  The INSPIRE-ASP PNA trial is a cluster-randomized controlled trial of HCA hospitals comparing routine empiric antibiotic stewardship practices with real-time precision medicine computerized physician order entry smart prompts providing the probability that a non-critically ill adult admitted with PNA is infected with a resistant pathogen. Note: that enrolled "subjects" represents 59 individual HCA hospitals that have been randomized.

  Riverside, California and other locations

• Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

  Sorry, in progress, not accepting new patients

  This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult patients with Coronavirus Disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Patients will be randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of the patients) or BSC alone (1/3 of the patients). Best supportive care will consist of medical treatment and/or medical interventions per routine hospital practice.

  Orange, California and other locations

• Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

  Sorry, in progress, not accepting new patients

  The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and improve ventilator-free survival in hospitalized subjects with severe or critical COVID-19 pneumonia.

  Irvine, California and other locations

Last updated: March 29, 2021